Danaher Corporation

271.20+3.70+1.38%Vol 835.33K1Y Perf -9.15%
Feb 2nd, 2023 12:08 DELAYED
BID271.14 ASK271.30
Open269.00 Previous Close267.50
Pre-Market269.54 After-Market-
 2.04 0.76%  - -
Target Price
310.50 
Analyst Rating
Strong Buy 1.44
Potential %
14.52 
Finscreener Ranking
★★★     48.91
Insiders Trans % 3/6/12 mo.
-67/-75/-95 
Value Ranking
★+     45.07
Insiders Value % 3/6/12 mo.
-99/-99/-100 
Growth Ranking
★★★★+     64.98
Insiders Shares Cnt. % 3/6/12 mo.
-99/-99/-100 
Income Ranking
★★     39.76
Price Range Ratio 52W %
53.47 
Earnings Rating
Sell
Market Cap197.51B 
Earnings Date
24th Jan 2023
Alpha0.01 Standard Deviation0.06
Beta0.83 

Today's Price Range

267.95273.24

52W Range

233.71303.82

5 Year PE Ratio Range

21.3068.40

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.62%
1 Month
0.78%
3 Months
10.29%
6 Months
-6.31%
1 Year
-9.15%
3 Years
66.28%
5 Years
161.79%
10 Years
347.41%

TickerPriceChg.Chg.%
DHR271.203.70001.38
AAPL149.664.23002.91
GOOG107.345.91325.83
MSFT260.968.20713.25
XOM111.75-2.9950-2.61
WFC47.290.26000.55
JNJ164.04-0.8798-0.53
FB196.640.99000.51
GE82.880.56000.68
JPM139.28-0.3100-0.22
 
ProfitabilityValueIndustryS&P 500US Markets
60.70
26.80
34.00
19.40
21.54
RevenueValueIndustryS&P 500US Markets
23.10B
31.74
15.37
9.03
DividendsValueIndustryS&P 500US Markets
0.39
1.00
8.76
8.85
Payout ratio10.00
Earnings HistoryEstimateReportedSurprise %
Q04 20222.462.8716.67
Q03 20222.242.5614.29
Q02 20222.352.7617.45
Q01 20222.652.764.15
Q04 20212.502.697.60
Q03 20212.142.3911.68
Q02 20212.042.4620.59
Q01 20211.672.5250.90
Earnings Per EndEstimateRevision %Trend
12/2022 QR2.44-7.58Negative
12/2022 FY10.531.25Positive
3/2023 QR2.49-7.09Negative
12/2023 FY10.38-2.54Negative
Next Report Date-
Estimated EPS Next Report2.46
Estimates Count9
EPS Growth Next 5 Years %12.00
Volume Overview
Volume835.33K
Shares Outstanding728.30K
Shares Float648.34M
Trades Count15.95K
Dollar Volume226.07M
Avg. Volume2.75M
Avg. Weekly Volume2.89M
Avg. Monthly Volume2.88M
Avg. Quarterly Volume2.48M

Danaher Corporation (NYSE: DHR) stock closed at 267.5 per share at the end of the most recent trading day (a 1.18% change compared to the prior day closing price) with a volume of 3.57M shares and market capitalization of 197.51B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 69000 people. Danaher Corporation CEO is Rainer M. Blair.

The one-year performance of Danaher Corporation stock is -9.15%, while year-to-date (YTD) performance is 0.78%. DHR stock has a five-year performance of 161.79%. Its 52-week range is between 233.708 and 303.82, which gives DHR stock a 52-week price range ratio of 53.47%

Danaher Corporation currently has a PE ratio of 27.90, a price-to-book (PB) ratio of 4.06, a price-to-sale (PS) ratio of 8.04, a price to cashflow ratio of 22.40, a PEG ratio of 2.32, a ROA of 8.80%, a ROC of 10.59% and a ROE of 16.73%. The company’s profit margin is 21.54%, its EBITDA margin is 34.00%, and its revenue ttm is $23.10 Billion , which makes it $31.74 revenue per share.

Of the last four earnings reports from Danaher Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.46 for the next earnings report. Danaher Corporation’s next earnings report date is -.

The consensus rating of Wall Street analysts for Danaher Corporation is Strong Buy (1.44), with a target price of $310.5, which is +14.52% compared to the current price. The earnings rating for Danaher Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Danaher Corporation has a dividend yield of 0.39% with a dividend per share of $1.00 and a payout ratio of 10.00%.

Danaher Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 10.91, ATR14 : 7.02, CCI20 : -2.04, Chaikin Money Flow : 0.22, MACD : 0.35, Money Flow Index : 49.70, ROC : -2.24, RSI : 50.86, STOCH (14,3) : 37.46, STOCH RSI : 0.62, UO : 54.99, Williams %R : -62.54), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Danaher Corporation in the last 12-months were: Alan G. Spoon (Option Excercise at a value of $177 292), Alan G. Spoon (Sold 500 shares of value $126 465 ), Brian W. Ellis (Sold 5 365 shares of value $1 577 247 ), Georgeann F. Couchara (Sold 1 884 shares of value $511 719 ), Jennifer Honeycutt (Option Excercise at a value of $540 530), Jennifer Honeycutt (Sold 11 988 shares of value $3 228 321 ), Joakim Weidemanis (Option Excercise at a value of $382 603), Joakim Weidemanis (Sold 28 008 shares of value $7 450 727 ), John T. Schwieters (Option Excercise at a value of $175 735), Matthew R. McGrew (Option Excercise at a value of $1 082 881), Matthew R. McGrew (Sold 18 935 shares of value $5 201 845 ), Mitchell P. Rales (Buy at a value of $24 789), Rainer M. Blair (Option Excercise at a value of $1 673 572), Rainer M. Blair (Sold 25 000 shares of value $7 500 000 ), Raymond C. Stevens (Option Excercise at a value of $851 686), Raymond C. Stevens (Sold 8 410 shares of value $2 222 514 ), Walter G. Lohr (Option Excercise at a value of $175 735), Walter G. Lohr (Sold 3 906 shares of value $1 069 619 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
12 (75.00 %)
12 (75.00 %)
11 (73.33 %)
Moderate Buy
1 (6.25 %)
1 (6.25 %)
1 (6.67 %)
Hold
3 (18.75 %)
3 (18.75 %)
3 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.44
Strong Buy
1.44
Strong Buy
1.47

Danaher Corporation

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.

CEO: Rainer M. Blair

Telephone: +1 202 828-0850

Address: 2200 Pennsylvania Avenue, North West, Washington 20037-1701, DC, US

Number of employees: 69 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

60%40%

Bearish Bullish

58%42%

TipRanks News for DHR

Wed, 25 Jan 2023 16:31 GMT Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Idexx Laboratories (IDXX) and Johnson & Johnson (JNJ)

- TipRanks. All rights reserved.

Tue, 24 Jan 2023 01:50 GMT Analysts Top Healthcare Picks: Danaher (DHR), Pliant Therapeutics (PLRX)

- TipRanks. All rights reserved.

Fri, 22 Jul 2022 14:42 GMT Danaher Posts Upbeat Q2 Results Street Says Buy

- TipRanks. All rights reserved.

Fri, 22 Jul 2022 12:57 GMT Analysts Top Healthcare Picks: Danaher (DHR), IQVIA Holdings (IQV)

- TipRanks. All rights reserved.

Fri, 22 Jul 2022 12:31 GMT Analysts Are Bullish on These Healthcare Stocks: Danaher (DHR), IQVIA Holdings (IQV)

- TipRanks. All rights reserved.

News

Stocktwits